Potentiation of cancer immunogenicity by targeting PARP
A team of scientists led by Quigley Goa demonstrates that Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) can induce tumor cell death in a manner that allows immune cells to better recognize and attack the tumor. Specifically, PARPi are approved for the treatment of tumors with homologous reco...
Saved in:
Main Authors: | Victoria Klepsch, Gottfried Baier, Dominik Humer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/6/e011056.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PARP Inhibition in Colorectal Cancer—A Comparison of Potential Predictive Biomarkers for Therapy
by: Abdulaziz Alfahed
Published: (2025-06-01) -
PARP9 and PARP14 are involved in microglia-mediated neuroinflammation in Alzheimer′s disease
by: HUANG Lian, WEI Hui
Published: (2025-05-01) -
Flaviviral Infections and Potential Targets for Antiviral Therapy
by: Baier, Andrea
Published: (2011) -
PARP inhibitors are a new area in the treatment of breast cancer
by: V. P. Letyagin
Published: (2014-08-01) -
Targeted but Troubling: CYP450 Inhibition by Kinase and PARP Inhibitors and Its Clinical Implications
by: Martin Kondža, et al.
Published: (2025-05-01)